by | May 18, 2022 | Publications
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0I190. ABSTRACT Although oncogenic mutations are considered the primary drivers of tumor initiation, latter steps in cancer progression including angiogenesis, invasion and metastasis are greatly influenced...
by | May 18, 2022 | Publications
Clin Cancer Res. 2022 May 13;28(10):2160-2166. doi: 10.1158/1078-0432.CCR-20-2995. ABSTRACT PURPOSE: Minimal residual disease (MRD) negativity is a strong predictor for outcome in multiple myeloma. To assess V(D)J clonotype capture using the updated Adaptive...
by | May 18, 2022 | Publications
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R4476. ABSTRACT The prevalence of allergic diseases such as Asthma, Rhinitis, Anaphylaxis, Eczema, Urticaria, and Angioedema have been rising dramatically in low- and middle-income countries around the...
by | May 18, 2022 | Publications
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.R6057. ABSTRACT Multiple myeloma (MM) is the second most common hematological cancer and remains incurable due to inevitable drug resistance. One contribution to drug resistance stems from the protective...
by | May 18, 2022 | Publications
FASEB J. 2022 May;36 Suppl 1. doi: 10.1096/fasebj.2022.36.S1.0R733. ABSTRACT OBJECTIVE: To examine whether there are changes in body fat composition and skeletal muscle density over a one-year period in a cohort of patients with multiple myeloma. HYPOTHESIS: We...
by | May 18, 2022 | Publications
Int J Mol Sci. 2022 Apr 25;23(9):4717. doi: 10.3390/ijms23094717. ABSTRACT Multiple Myeloma (MM) is a devastating malignancy that evades immune destruction using multiple mechanisms. The NKp44 receptor interacts with PCNA (Proliferating Cell Nuclear Antigen) and may...
